PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2016 October; 60(10): 5649–5654.
Published online 2016 September 23. Prepublished online 2016 July 11. doi:  10.1128/AAC.00920-16
PMCID: PMC5038325

Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity

Abstract

Dihydroartemisinin-piperaquine (DP) offers prolonged protection against malaria, but its impact on Plasmodium falciparum drug sensitivity is uncertain. In a trial of intermittent preventive treatment in schoolchildren in Tororo, Uganda, in 2011 to 2012, monthly DP for 1 year decreased the incidence of malaria by 96% compared to placebo; DP once per school term offered protection primarily during the first month after therapy. To assess the impact of DP on selection of drug resistance, we compared the prevalence of key polymorphisms in isolates that emerged at different intervals after treatment with DP. Blood obtained monthly and at each episode of fever was assessed for P. falciparum parasitemia by microscopy. Samples from 160 symptomatic and 650 asymptomatic episodes of parasitemia were assessed at 4 loci (N86Y, Y184F, and D1246Y in pfmdr1 and K76T in pfcrt) that modulate sensitivity to aminoquinoline antimalarials, utilizing a ligase detection reaction-fluorescent microsphere assay. For pfmdr1 N86Y and pfcrt K76T, but not the other studied polymorphisms, the prevalences of mutant genotypes were significantly greater in children who had received DP within the past 30 days than in those not treated within 60 days (86Y, 18.0% versus 8.3% [P = 0.03]; 76T, 96.0% versus 86.1% [P = 0.05]), suggesting selective pressure of DP. Full sequencing of pfcrt in a subset of samples did not identify additional polymorphisms selected by DP. In summary, parasites that emerged soon after treatment with DP were more likely than parasites not under drug pressure to harbor pfmdr1 and pfcrt polymorphisms associated with decreased sensitivity to aminoquinoline antimalarials. (This study has been registered at ClinicalTrials.gov under no. NCT01231880.)

INTRODUCTION

Malaria, in particular infection with Plasmodium falciparum, remains a huge public health problem, with the highest disease burden in sub-Saharan Africa (1, 2). Important advances have been made in malaria control recently, with a significant decrease in malaria burden and progress toward elimination noted in some areas (3). Among key tools in the control of malaria is intermittent preventive treatment (IPT), the provision of full treatment courses at regular intervals to high-risk populations (4). IPT is standard practice during pregnancy (IPTp), is recommended for children living in seasonal malaria transmission settings as seasonal malaria chemoprevention (5), and is being investigated in other populations (6,9). However, currently IPT is advocated only with sulfadoxine-pyrimethamine (SP) or a combination of SP and amodiaquine (SP-AQ) (5, 10), regimens that are severely compromised by drug resistance in much of Africa (11,13). For malaria treatment, older regimens have been replaced by artemisinin-based combination therapies (ACTs), and a similar change may be warranted for IPT.

Dihydroartemisinin-piperaquine (DP), which provides rapid killing of most parasites by dihydroartemisinin, prolonged action against any remaining parasites by piperaquine, and protection for weeks after therapy due to the long half-life of piperaquine, has recently been investigated for IPT. Compared to IPTp with SP, IPTp with DP was associated with lower risks of P. falciparum infection and symptomatic malaria during pregnancy in Kenya (14) and Uganda (15). In Ugandan schoolchildren, monthly IPT with DP was associated with a reduced incidence of malaria and reduced prevalence of parasitemia and anemia compared to DP given approximately once every 3 months or placebo (6, 16). Similar results were observed in Ugandan infants when monthly IPT with DP was compared with daily trimethoprim-sulfamethoxazole or monthly SP (7). Thus, DP is a promising alternative to SP or SP-AQ for IPT, but its benefits may be undone by the emergence of P. falciparum resistance to either component of the combination.

Mediators of decreased drug sensitivity and selective pressures for resistance are quite well understood for some antimalarial drugs. Resistance to the aminoquinolines chloroquine and amodiaquine is mediated largely by polymorphisms in putative drug transporters encoded by pfcrt and pfmdr1 (13, 17), and these polymorphisms are selected in new infections that emerge soon after therapy with artesunate-AQ (AS-AQ) (18, 19). Piperaquine is a bisaminoquinoline related to chloroquine and amodiaquine. Resistance to piperaquine was widely reported during the preartemisinin era in China (20), and recently clinically relevant resistance, with frequent recrudescences after therapy with DP, has been noted in Cambodia (21,23). However, mechanisms of resistance to piperaquine are uncertain. Use of DP for treatment (24) or chemoprevention (25) did not select for the polymorphisms associated with chloroquine resistance in Burkina Faso, but in Uganda recent treatment with DP selected for pfmdr1 mutations associated with decreased sensitivity to aminoquinolines (26). Interestingly, some other antimalarials, notably lumefantrine, which is a component of the Ugandan first-line antimalarial regimen artemether-lumefantrine (AL), exert the opposite selective pressure. Thus, new infections emerging within 2 months of treatment with AL showed selection of wild-type sequences at the pfcrt K76T and pfmdr1 N86Y and D1246Y alleles (26,29); mutant sequences are selected at these same alleles by aminoquinolines. Of recent concern has been resistance to artemisinins, manifest as delayed parasite clearance after therapy, in Southeast Asia (22, 30,32), but recent studies utilizing clinical, parasitological, and molecular markers (33, 34) suggest that the artemisinin-resistant phenotype is not yet prevalent in Uganda (26, 35, 36) or other parts of Africa (37, 38).

Taken together, the available evidence suggests that DP may select for the same P. falciparum polymorphisms as other aminoquinolines, leading to decreased treatment or preventive efficacy of DP, but data on the effects of IPT with DP are very limited. We therefore assessed the prevalences of key polymorphisms in isolates that emerged at different intervals after treatment with DP using samples from a recent trial evaluating IPT with DP in Ugandan schoolchildren.

MATERIALS AND METHODS

Clinical trial.

Study samples were from a randomized, double-blinded, placebo-controlled trial conducted in Tororo, Uganda, from 2011 to 2012 (6, 39). In brief, 740 schoolchildren aged 6 to 14 years from one primary school in Mulanda subcounty, Tororo District, were enrolled and randomized 1:1:1 to one of three study arms: DP monthly, DP once per school term (four treatments over 12 months), or placebo. DP was administered according to weight-based guidelines, and treatment was directly observed. Finger-prick blood samples were obtained at enrollment, every month, and with every episode of fever to assess for malaria infection by thick blood smear and for storage on filter paper. Episodes of uncomplicated malaria were treated with AL. Children were followed for 12 months. The trial was approved by the Uganda National Council for Science and Technology and the Makerere University School of Medicine Research and Ethics Committee and registered at ClinicalTrials.gov (NCT01231880). Molecular studies were also approved by the University of California, San Francisco, Committee on Human Research.

Selection of samples for testing of parasite polymorphisms.

We considered all samples that were positive for P. falciparum parasitemia based on evaluation of Giemsa-stained thick blood smears, as previously described (6). A total of 160 symptomatic and 1,522 asymptomatic episodes of P. falciparum parasitemia were documented. The number of samples analyzed was determined by estimating the power for two-sample comparison of proportions using effect sizes observed for each mutant polymorphism in a recent study in Tororo (0.34 for pfmdr1 N86Y, 0.11 for pfmdr1 D1246Y, 0.04 for pfmdr1 184F, and 0.09 for pfcrt K76), fixing α at 0.05 (26). The sample size giving the maximum power was considered in the analysis. From these estimates, we analyzed all 160 samples from symptomatic episodes, all 50 samples from children with recurrent parasitemia within 13 to 30 days of prior therapy with DP, and 600 samples randomly selected from children with either recurrent parasitemia >30 days after prior therapy with DP or from the control arm of the study. All samples were analyzed for 4 common P. falciparum polymorphisms known to be associated with drug sensitivity: pfcrt K76T, and pfmdr1 N86Y, Y184F, and D1246Y. A subset of 25 samples from children with prior DP therapy within 13 to 30 days and 25 randomly selected paired samples from children in the control arm (each pair matched for collection within 15 days of each other) were subjected to sequencing of the complete pfcrt gene.

Characterization of 4 pfcrt and pfmdr1 polymorphisms.

DNA was extracted from filter paper blood spots into 100 μl of water using Chelex-100 as previously described (40). Gene fragments spanning all loci of interest were amplified in nested reactions (26), and failed reactions were repeated. To detect polymorphisms, multiplex ligase detection reaction-fluorescent microsphere assays were performed as previously described (26, 41).

Sequencing of pfcrt.

For a subset of samples, pfcrt was sequenced from DNA samples as previously described (42) with minor modifications. Briefly, pfcrt was amplified in 3 nested PCRs, covering exons 1 and 2, 3 to 8, and 9 to 13, using the published primer sequences. For both rounds of PCR, each 25-μl reaction mixture contained 2 mM MgSO4, 200 μM each deoxynucleoside triphosphate (dNTP), 1 μM each primer, 1× PCR buffer, and 2 U Platinum Taq high-fidelity DNA polymerase (Invitrogen). Conditions for all reactions were 94°C for 2 min, 30 cycles of 94°C for 20 s, 47°C for 10 s, and 60°C for 3 min, and a final extension at 60°C for 5 min. Amplicons were cloned with the TOPO-TA cloning kit for sequencing and transfected into One Shot TOP10 chemically competent Escherichia coli (Invitrogen) according to the manufacturer's instructions. Colonies were grown overnight under kanamycin selection, picked, and incubated in LB broth with kanamycin. Plasmid DNA was purified using the PureLink quick plasmid miniprep kit (Invitrogen), digested with EcoRI to confirm the insert size, and then sequenced (Eurofins) using M13 forward and reverse primers. DNA sequence data were assembled and edited, and mutations were detected by alignment and comparison to the expected sequence using CodonCode Aligner v. 5.1.5. Multiple clones were sequenced to distinguish true polymorphisms from PCR errors, including at least 3 clones for all but 3 fragments, for which 2 clones were sequenced.

Statistical analysis.

Data analysis was done using Stata version 14 (StataCorp). Outcomes of interest were the prevalence of pure mutant alleles for each locus of interest. The exposure variable of interest was duration since prior DP dose, evaluated as a categorical variable split into 13 to 30, 31 to 60, and >60 days (including the no-treatment control group) since the last treatment. Associations between outcomes and duration since last treatment and differences between prevalences of pfcrt alleles were measured using Fisher's exact test and expressed as relative risk. In all analyses, a 2-tailed P value of <0.05 was considered statistically significant.

RESULTS

Study samples.

A total of 740 schoolchildren aged 6 to 14 years were randomized to one of the three study arms in the parent study and followed for 1 year from 2011 to 2012. As previously reported, compared to either DP once per school term (approximately every 3 months) or placebo, monthly DP offered strong protective efficacy against malaria (6). For this substudy, samples collected from children with blood smears positive for P. falciparum were analyzed (Table 1). As expected due to the protective efficacy of monthly DP, fewer samples were available from this study arm than from children who received placebo or DP once per school term. A total of 810 samples from 160 symptomatic and 650 asymptomatic episodes of parasitemia were assessed (Table 1). Samples were analyzed for common polymorphisms in pfmdr1 and pfcrt. Genotyping results were available for pfcrt K76T in 806 (99.5%) samples and for pfmdr1 N86Y, N184Y, and D1246Y in 800 (98.8%), 810 (100%), and 784 (96.8%) samples, respectively, and these results were included in the analysis.

TABLE 1
Characteristics of children who supplied samples and of episodes selected for analysis

Prevalence of pfcrt and pfmdr1 polymorphisms.

The prevalence of the 4 studied polymorphisms was similar to that in contemporaneous samples from Tororo that were reported previously (43). For two polymorphisms, pfcrt K76T and pfmdr1 N86Y, the prevalence of mutant genotypes was significantly higher in samples from children who had received DP within 30 days than in those from children who had not received DP within 60 days (Table 2). For the other studied polymorphisms, the prevalence of genotypes did not differ between children who had or had not received recent therapy with DP. Matching for duration since a prior episode, there was no difference in the prevalence of pfcrt and pfmdr1 mutant alleles between samples from children with symptomatic or asymptomatic parasitemia (data not shown).

TABLE 2
Prevalence of P. falciparum pure mutant alleles stratified by time since last dose of DP

Sequencing of pfcrt.

As DP may select for additional polymorphisms in pfcrt, we sequenced the gene in a subset of 25 parasitemic samples under strong selective pressure as indicated by emergence within 30 days of prior therapy with DP and in 25 paired samples collected near the same date from children who did not receive DP. We successfully sequenced the full gene in 17 pairs. We identified 9 polymorphisms, 6 of which are commonly reported in African isolates (see Table S1 in the supplemental material). All isolates had the pfcrt 72-76 CVIET or a mix of the CVIET and CVMNT haplotype, except for one isolate that had the pfcrt 72S mutation, resulting in the SVIET haplotype (in all 6 clones from a patient not receiving DP). Two additional polymorphisms, L50P and F112I, were each identified in at least 2 clones from a single isolate, the 50P mutation in a control isolate and the 112I mutation in an isolate from a child recently treated with DP (see Table S2 in the supplemental material). We found 9 pfcrt haplotypes; the majority (76% in the DP arm and 65% in the control arm) were mutant at the six loci that are commonly mutant in Africa (74I, 75E, 76T, 220S, 271E, and 371I) (17). Overall, we saw no evidence that DP selected for novel pfcrt polymorphisms in Ugandan children.

DISCUSSION

Monthly IPT with DP was highly efficacious in reducing the risks of symptomatic malaria, parasitemia, and anemia in Ugandan schoolchildren (6). However, the chemoprophylactic benefits of a long-acting antimalarial such as piperaquine may be accompanied by selection of drug-resistant parasites (13). We tested whether DP selected for parasites with genotypes associated with altered sensitivity to aminoquinolines. Compared to parasites not under drug pressure, those that emerged within 30 days of IPT with DP were more likely to harbor two mutations, pfmdr1 86Y and pfcrt 76T; these mutations are associated with resistance to chloroquine and amodiaquine (36, 43,45). Thus, the marked preventive efficacy of IPT with DP may be accompanied by selection of decreased sensitivity to aminoquinolines.

Resistance to chloroquine and amodiaquine is mediated primarily by polymorphisms in putative drug transporters encoded by pfcrt and pfmdr1 (13, 17). The pfcrt 76T and pfmdr1 86Y and 1246Y mutations are selected in new infections that emerge soon after therapy with regimens including chloroquine or amodiaquine (46). Piperaquine is a related bisaminoquinoline, but mechanisms of resistance are uncertain, and studies of the selective pressure exerted by DP have yielded conflicting results. Specifically, use of DP for treatment (24) or chemoprevention (25) did not select for the polymorphisms associated with aminoquinoline resistance in Burkina Faso, but in Uganda, recent treatment with DP selected for the pfmdr1 86Y and 1246Y mutations (26). Our new results shed additional light on this area. In the setting of IPT in schoolchildren, recent receipt of DP was associated with selection of the pfmdr1 86Y and pfcrt 76T mutations but not the pfmdr1 1246Y mutation. The differing results may have been due to the changing baseline of polymorphism prevalence in Uganda, with decreasing prevalence of pfmdr1 1246Y and pfcrt 76T over time. Differences in results between West and East Africa may also be explained by differences in parasite backgrounds; of note, the pfmdr1 1246Y mutation, which until recently was widespread in Uganda, has consistently been uncommon in Burkina Faso (24, 25, 28).

Importantly, although we lack a head-to-head comparison, it appears that DP does not select as readily as other ACTs for key transporter mutations. In multiple studies, the selective pressure of AS/AQ was marked (47), including a recent trial that showed the prevalence of the pure pfmdr1 86Y mutation to rise from 59% at baseline to 99% in recurrent infections within 1 month of treatment (48). AL also exerts strong selective pressure, but in the opposite direction, with selection of wild-type pfcrt K76 and pfmdr1 N86 and N1246 sequences in parasites that emerge soon after therapy (19, 29). Our recent findings indicate that DP selects for resistance in a manner similar to that of the other aminoquinolines, but associations between recent therapy and transporter polymorphisms were less marked, suggesting that the selective pressure of DP is lower than that of other regimens. This difference might be due to different mechanisms of transport for piperaquine, a much larger molecule than chloroquine or amodiaquine.

We were concerned that IPT with DP might select for additional resistance-mediating P. falciparum polymorphisms. Polymorphisms in addition to those commonly described in African isolates have been identified in other regions, in some cases with biochemical and clinical consequences (49, 50). Sequencing of pfcrt in a subset of samples either under or not under the selective pressure of DP identified a few previously unidentified pfcrt mutations, but it did not suggest that additional polymorphisms were selected by DP.

Our results have important implications for the use of DP for IPT. Although it offers great promise for decreasing the malaria burden, DP use may be accompanied by selection of parasites with decreased sensitivity to DP and also to the related ACT AS-AQ. Consideration of the opposite resistance pressures of different antimalarials has led some to recommend multiple or rotating first-line antimalarial regimens (51). For example, AS-AQ and AL have opposite selective pressures on pfcrt and pfmdr1 such that each regimen should blunt selection of resistance to the other. Our results are consistent with a prior study in Uganda indicating that DP has selective pressure similar to that of AS-AQ. Thus, considering resistance selection, using DP in IPT might be best advised when the standard treatment regimen is AL, such that the treatment and IPT regimens offer mutual protection against selection of resistance. Further, our results suggest that, with changing treatment and control practices, continued surveillance for clinical, biochemical, and molecular markers of antimalarial drug resistance in Africa is an important priority.

Supplementary Material

Supplemental material:

ACKNOWLEDGMENTS

We thank the participants in the clinical trials from whom the samples were collected, their parents and guardians, and our clinical study team, including Pauline Mary Amuge Kayiga, Sarah Nabwire, Victor Asua, Immaculate Mary Nandera, Twaha Yiga, Godfrey Odoi, and Daniel James Owino.

This work was supported by the Malaria Capacity Development Consortium (WT084289MA), the Bill & Melinda Gates Foundation (51941), and grants from the National Institutes of Health (AI075045 and AI089674). Bonnie Wandera is a THRiVE fellow supported by the Wellcome Trust (087540), and Simon J Brooker was supported by a Wellcome Trust Senior Fellowship in Basic Biomedical Sciences (098045).

All authors report no conflicts of interest.

Funding Statement

This work, including the efforts of Joaniter I. Nankabirwa, was funded by Malaria Capacity Development Consortium through a grant from Bill & Melinda Gates Foundation (51941) and a grant from Wellcome Trust (WT084289MA). This work, including the efforts of Bonnie Wandera, was funded by THRiVE through a grant from Wellcome Trust (087540). Part of the lab work for this study was funded by HHS | National Institutes of Health (NIH) (AI075045 and AI089674). This work, including the efforts of Simon J. Brooker, was funded by Wellcome Trust (098045).

Footnotes

Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.00920-16.

REFERENCES

1. World Health Organization. 2015. World malaria report 2015. http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/ World Health Organization, Geneva, Switzerland.
2. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM 2014. Malaria. Lancet 383:723–735. doi:.10.1016/S0140-6736(13)60024-0 [PubMed] [Cross Ref]
3. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, Sabot O, Rodriguez MH, Abeyasinghe RR, Ghebreyesus TA, Snow RW 2010. Shrinking the malaria map: progress and prospects. Lancet 376:1566–1578. doi:.10.1016/S0140-6736(10)61270-6 [PMC free article] [PubMed] [Cross Ref]
4. Gosling RD, Cairns ME, Chico RM, Chandramohan D 2010. Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther 8:589–606. doi:.10.1586/eri.10.36 [PubMed] [Cross Ref]
5. World Health Organization Global Malaria Programme. 2012. WHO policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. World Health Organization, Geneva, Switzerland: http://www.who.int/malaria/publications/atoz/who_smc_policy_recommendation/en/.
6. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR 2014. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 58:1404–1412. doi:.10.1093/cid/ciu150 [PMC free article] [PubMed] [Cross Ref]
7. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G 2014. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 11:e1001689. doi:.10.1371/journal.pmed.1001689 [PMC free article] [PubMed] [Cross Ref]
8. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C 2009. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374:1533–1542. doi:.10.1016/S0140-6736(09)61258-7 [PubMed] [Cross Ref]
9. Clarke SE, Jukes MC, Njagi JK, Khasakhala L, Cundill B, Otido J, Crudder C, Estambale BB, Brooker S 2008. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 372:127–138. doi:.10.1016/S0140-6736(08)61034-X [PMC free article] [PubMed] [Cross Ref]
10. World Health Organization. 2012. Updated WHO policy recommendation: intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). World Health Organization, Geneva, Switzerland: http://www.who.int/malaria/publications/atoz/who_iptp_sp_policy_recommendation/en/.
11. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, Duffy PE 2009. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A 106:9027–9032. doi:.10.1073/pnas.0901415106 [PubMed] [Cross Ref]
12. Singana BP, Bogreau H, Matondo BD, Dossou-Yovo LR, Casimiro PN, Mbouka R, Ha Nguyen KY, Pradines B, Basco LK, Ndounga M 2016. Malaria burden and anti-malarial drug efficacy in Owando, northern Congo. Malar J 15:16. doi:.10.1186/s12936-015-1078-4 [PMC free article] [PubMed] [Cross Ref]
13. Rosenthal PJ. 2013. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol 89:1025–1038. doi:.10.1111/mmi.12349 [PMC free article] [PubMed] [Cross Ref]
14. Desai M, Gutman J, L'Lanziva A, Otieno K, Juma E, Kariuki S, Ouma P, Were V, Laserson K, Katana A, Williamson J, ter Kuile FO 2015. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet 386:2507–2519. doi:.10.1016/S0140-6736(15)00310-4 [PMC free article] [PubMed] [Cross Ref]
15. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opira B, Olwoch P, Ategeka J, Nayebare P, Clark TD, Feeney ME, Charlebois ED, Rizzuto G, Muehlenbachs A, Havlir DV, Kamya MR, Dorsey G 2016. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med 374:928–939. doi:.10.1056/NEJMoa1509150 [PMC free article] [PubMed] [Cross Ref]
16. Nankabirwa J, Cundill B, Clarke S, Kabatereine N, Rosenthal PJ, Dorsey G, Brooker S, Staedke SG 2010. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One 5:e13438. doi:.10.1371/journal.pone.0013438 [PMC free article] [PubMed] [Cross Ref]
17. Ecker A, Lehane AM, Clain J, Fidock DA 2012. PfCRT and its role in antimalarial drug resistance. Trends Parasitol 28:504–514. doi:.10.1016/j.pt.2012.08.002 [PMC free article] [PubMed] [Cross Ref]
18. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ 2007. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother 51:3023–3025. doi:.10.1128/AAC.00012-07 [PMC free article] [PubMed] [Cross Ref]
19. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, Hallett RL 2007. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 51:991–997. doi:.10.1128/AAC.00875-06 [PMC free article] [PubMed] [Cross Ref]
20. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65:75–87. doi:.10.2165/00003495-200565010-00004 [PubMed] [Cross Ref]
21. Fairhurst RM. 2015. Understanding artemisinin-resistant malaria: what a difference a year makes. Curr Opin Infect Dis 28:417–425. doi:.10.1097/QCO.0000000000000199 [PMC free article] [PubMed] [Cross Ref]
22. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D, Song L, Tullo GS, Fay MP, Anderson JM, Tarning J, Fairhurst RM 2016. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 16:357–365. doi:.10.1016/S1473-3099(15)00487-9 [PMC free article] [PubMed] [Cross Ref]
23. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul M, Sia-ngam P, Kuntawunginn W, Arsanok M, Buathong N, Chaorattanakawee S, Gosi P, Ta-aksorn W, Chanarat N, Sundrakes S, Kong N, Heng TK, Nou S, Teja-isavadharm P, Pichyangkul S, Phann ST, Balasubramanian S, Juliano JJ, Meshnick SR, Chour CM, Prom S, Lanteri CA, Lon C, Saunders DL 2015. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 15:683–691. doi:.10.1016/S1473-3099(15)70049-6 [PubMed] [Cross Ref]
24. Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouedraogo JB, Rosenthal PJ 2010. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 54:1949–1954. doi:.10.1128/AAC.01413-09 [PMC free article] [PubMed] [Cross Ref]
25. Some AF, Zongo I, Compaore YD, Sakande S, Nosten F, Ouedraogo JB, Rosenthal PJ 2014. Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother 58:3660–3665. doi:.10.1128/AAC.02406-14 [PMC free article] [PubMed] [Cross Ref]
26. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis 210:344–353. doi:.10.1093/infdis/jiu141 [PMC free article] [PubMed] [Cross Ref]
27. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191:1014–1017. doi:.10.1086/427997 [PubMed] [Cross Ref]
28. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, Ouedraogo JB 2007. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45:1453–1461. doi:.10.1086/522985 [PubMed] [Cross Ref]
29. Baliraine FN, Rosenthal PJ 2011. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis 204:1120–1124. doi:.10.1093/infdis/jir486 [PMC free article] [PubMed] [Cross Ref]
30. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619–2620. doi:.10.1056/NEJMc0805011 [PubMed] [Cross Ref]
31. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TJ, Fay MP, Mu J, Duong S, Fairhurst RM 2012. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 12:851–858. doi:.10.1016/S1473-3099(12)70181-0 [PMC free article] [PubMed] [Cross Ref]
32. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455–467. doi:.10.1056/NEJMoa0808859 [PMC free article] [PubMed] [Cross Ref]
33. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WR, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D 2013. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis 13:1943–1949. [PMC free article] [PubMed]
34. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50–55. doi:.10.1038/nature12876 [PMC free article] [PubMed] [Cross Ref]
35. Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, Arinaitwe E, Tappero JW, Kaharuza F, Kamya MR, Dorsey G 2014. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J 13:32. doi:.10.1186/1475-2875-13-32 [PMC free article] [PubMed] [Cross Ref]
36. Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, Kozak B, Bloome J, Okiring J, Kakuru A, Bigira V, Kapisi J, Legac J, Gut J, Cooper RA, Kamya MR, Havlir DV, Dorsey G, Greenhouse B, Nsobya SL, Rosenthal PJ 2015. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from Ugandan children. Antimicrob Agents Chemother 59:3018–3030. doi:.10.1128/AAC.05141-14 [PMC free article] [PubMed] [Cross Ref]
37. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, et al. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371:411–423. doi:.10.1056/NEJMoa1314981 [PMC free article] [PubMed] [Cross Ref]
38. Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, Tagbor H, Williams J, Bojang K, Njie F, Desai M, Kariuki S, Gutman J, Mathanga DP, Martensson A, Ngasala B, Conrad MD, Rosenthal PJ, Tshefu AK, Moormann AM, Vulule JM, Doumbo OK, Ter Kuile FO, Meshnick SR, Bailey JA, Juliano JJ 2015. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 211:680–688. doi:.10.1093/infdis/jiu467 [PMC free article] [PubMed] [Cross Ref]
39. Nankabirwa J, Wandera B, Kiwanuka N, Staedke SG, Kamya MR, Brooker SJ 2013. Asymptomatic Plasmodium infection and cognition among primary schoolchildren in a high malaria transmission setting in Uganda. Am J Trop Med Hyg 88:1102–1108. doi:.10.4269/ajtmh.12-0633 [PMC free article] [PubMed] [Cross Ref]
40. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52:565–568. [PubMed]
41. LeClair NP, Conrad MD, Baliraine FN, Nsanzabana C, Nsobya SI, Rosenthal PJ 2013. Optimization of a ligase detection reaction-fluorescent microsphere assay for characterization of resistance-mediating polymorphisms in African samples of Plasmodium falciparum. J Clin Microbiol 51:2564–2570. doi:.10.1128/JCM.00904-13 [PMC free article] [PubMed] [Cross Ref]
42. Chaijaroenkul W, Ward SA, Mungthin M, Johnson D, Owen A, Bray PG, Na-Bangchang K 2011. Sequence and gene expression of chloroquine resistance transporter (pfcrt) in the association of in vitro drugs resistance of Plasmodium falciparum. Malar J 10:42. doi:.10.1186/1475-2875-10-42 [PMC free article] [PubMed] [Cross Ref]
43. Mbogo GW, Nankoberanyi S, Tukwasibwe S, Baliraine FN, Nsobya SL, Conrad MD, Arinaitwe E, Kamya M, Tappero J, Staedke SG, Dorsey G, Greenhouse B, Rosenthal PJ 2014. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am J Trop Med Hyg 91:54–61. doi:.10.4269/ajtmh.13-0647 [PMC free article] [PubMed] [Cross Ref]
44. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A 2009. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 53:5069–5073. doi:.10.1128/AAC.00638-09 [PMC free article] [PubMed] [Cross Ref]
45. Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, Juma D, Yeda R, Andagalu B, Wanja E, Kamau E, Schnabel D, Bulimo W, Waters NC, Walsh DS, Johnson JD 2013. The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011. PLoS One 8:e64299. doi:.10.1371/journal.pone.0064299 [PMC free article] [PubMed] [Cross Ref]
46. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257–263. doi:.10.1056/NEJM200101253440403 [PubMed] [Cross Ref]
47. Sondo P, Derra K, Diallo Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, Valea I, Sorgho H, Owusu-Dabo E, Ouedraogo JB, Guiguemde TR, Tinto H 2016. Artesunate-amodiaquine and artemether-lumefantrine therapies and selection of Pfcrt and Pfmdr1 alleles in Nanoro, Burkina Faso. PLoS One 11:e0151565. doi:.10.1371/journal.pone.0151565 [PMC free article] [PubMed] [Cross Ref]
48. Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, Belay K, Kapella BK, Chang MA, Kamya MR, Staedke SG, Dorsey G, Rosenthal PJ 2016. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis 213:1134–1142. doi:.10.1093/infdis/jiv551 [PMC free article] [PubMed] [Cross Ref]
49. Petersen I, Gabryszewski SJ, Johnston GL, Dhingra SK, Ecker A, Lewis RE, de Almeida MJ, Straimer J, Henrich PP, Palatulan E, Johnson DJ, Coburn-Flynn O, Sanchez C, Lehane AM, Lanzer M, Fidock DA 2015. Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol Microbiol 97:381–395. doi:.10.1111/mmi.13035 [PMC free article] [PubMed] [Cross Ref]
50. Pelleau S, Moss EL, Dhingra SK, Volney B, Casteras J, Gabryszewski SJ, Volkman SK, Wirth DF, Legrand E, Fidock DA, Neafsey DE, Musset L 2015. Adaptive evolution of malaria parasites in French Guiana: reversal of chloroquine resistance by acquisition of a mutation in pfcrt. Proc Natl Acad Sci U S A 112:11672–11677. doi:.10.1073/pnas.1507142112 [PubMed] [Cross Ref]
51. Sutherland CJ, Babiker H, Mackinnon MJ, Ranford-Cartwright L, El Sayed BB 2011. Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases? Parasitology 138:1459–1468. doi:.10.1017/S0031182011001144 [PMC free article] [PubMed] [Cross Ref]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)